Cerebrospinal fluid levels of amyloid β-peptide1-42, but not tau have positive correlation with brain glucose metabolism in humans

Nobuyuki Okamura, Hiroyuki Arai, Makoto Higuchi, Manabu Tashiro, Toshifumi Matsui, Masatoshi Itoh, Takeshi Iwatsubo, Taisuke Tomita, Hidetada Sasaki

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)

Abstract

To address the question of whether assay for cerebrospinal fluid (CSF) levels of amyloid β-peptide 1-42 (Aβ1-42) and tau allow us to monitor the neurodegenerative processes that lead to a progressive and massive death of neurons in Alzheimer's disease (AD) and non-AD patients, cerebral glucose metabolism using 2-[18F] fluoro-2-deoxy-glucose was quantified by positron emission tomography in fifteen AD patients and nine non-AD patients with defined levels of CSF-Aβ1-42 and CSF-tau. The CSF-Aβ1-42 levels, but not the CSF-tau levels, in both AD and non-AD patients consistently and significantly correlated with global and, in particular, temporal lobe glucose metabolism. Results from our study suggest that the CSF-Aβ1-42 levels may reflect residual brain function and help monitoring progression of dementing disorders. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)203-207
Number of pages5
JournalNeuroscience Letters
Volume273
Issue number3
DOIs
Publication statusPublished - 1999 Oct 8

Keywords

  • Alzheimer's disease
  • Amyloid β-peptide 1-42
  • Cerebral glucose metabolism
  • Cerebrospinal fluid
  • Positron emission tomography
  • Tau

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Cerebrospinal fluid levels of amyloid β-peptide<sub>1-42</sub>, but not tau have positive correlation with brain glucose metabolism in humans'. Together they form a unique fingerprint.

Cite this